PDS Biotechnology Announces $11.1M Securities Purchase Agreement

PDS Biotechnology ( (PDSB) ) just unveiled an update.

On November 11, 2025, PDS Biotechnology Corporation announced a securities purchase agreement to raise up to $11.1 million through the sale of common stock and warrants, with the offering expected to close on November 12, 2025. The proceeds will support the company’s ongoing VERSATILE-003 Phase 3 clinical trial and other research and development activities, potentially impacting its operational capabilities and market position.

The most recent analyst rating on (PDSB) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on PDS Biotechnology stock, see the PDSB Stock Forecast page.

Spark’s Take on PDSB Stock

According to Spark, TipRanks’ AI Analyst, PDSB is a Neutral.

PDSB’s overall score reflects the typical high-risk, high-reward nature of early-stage biotech firms. The company’s strong clinical progress and cash position are significant positives, but financial sustainability and valuation concerns due to ongoing losses and reliance on external funding temper the outlook. Technical indicators suggest some positive momentum, albeit with caution.

To see Spark’s full report on PDSB stock, click here.

More about PDS Biotechnology

PDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers. The company is advancing its lead program in advanced HPV16-positive head and neck squamous cell cancers and is developing its lead investigational targeted immunotherapy, PDS0101, in combination with standard-of-care treatments.

Average Trading Volume: 730,576

Technical Sentiment Signal: Sell

Current Market Cap: $45.84M

For detailed information about PDSB stock, go to TipRanks’ Stock Analysis page.